OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis

An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Subjects With Renal Anemia, Treated With MIRCERA (Methoxy-Polyethylene-Glycol-Epoetin Beta)

This prospective observational study evaluated the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease participants on dialysis with renal anemia. Participants initiated on treatment with Mircera according to the Summary of Product Characteristics and standard clinical practice were followed for 10 months.

Inclusion Criteria:

• Adult participants, >/= 18 years of age
• Participants with chronic kidney disease (CKD) not on dialysis with renal anemia (CKD Stages 3 & 4)
• Initiated on Mircera treatment (participants may have received Mircera treatment for up to 3 months before study enrollment)
• Life expectancy > 10 months

Exclusion Criteria:

• Malignant disease
• Significant or acute bleeding
• Poorly controlled hypertension
• Blood transfusion during the previous 2 months
• Hypersensitivity to Mircera or any of its excipients